IGMS
Income statement / Annual
Last year (2024), IGM Biosciences, Inc.'s total revenue was $2.68 M,
an increase of 25.77% from the previous year.
In 2024, IGM Biosciences, Inc.'s net income was -$195.80 M.
See IGM Biosciences, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
| Operating Revenue |
$2.68 M |
$2.13 M |
$1.07 M |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$9.11 M
|
$8.28 M
|
$10.60 M
|
$7.72 M
|
$3.58 M
|
$2.33 M
|
$278.00 K
|
$161.00 K
|
| Gross Profit |
-$6.43 M
|
-$6.15 M
|
-$9.53 M
|
-$7.72 M
|
-$3.58 M
|
-$2.33 M
|
-$278.00 K
|
-$161.00 K
|
| Gross Profit Ratio |
-2.4
|
-2.89
|
-8.92
|
0
|
0
|
0
|
0
|
0
|
| Research and Development Expenses |
$160.85 M
|
$215.52 M
|
$179.29 M
|
$127.03 M
|
$65.03 M
|
$35.26 M
|
$18.96 M
|
$8.64 M
|
| General & Administrative Expenses |
$50.41 M
|
$50.07 M
|
$49.74 M
|
$38.30 M
|
$18.25 M
|
$9.24 M
|
$3.83 M
|
$2.51 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$50.41 M
|
$50.07 M
|
$49.74 M
|
$38.30 M
|
$18.25 M
|
$9.24 M
|
$3.83 M
|
$2.51 M
|
| Other Expenses |
$0.00
|
$0.00
|
-$181.00 K
|
$159.00 K
|
$1.93 M
|
$1.37 M
|
$80.00 K
|
$93.00 K
|
| Operating Expenses |
$211.26 M
|
$265.59 M
|
$229.03 M
|
$165.32 M
|
$83.28 M
|
$44.50 M
|
$22.79 M
|
$11.15 M
|
| Cost And Expenses |
$211.26 M
|
$265.59 M
|
$229.03 M
|
$165.32 M
|
$83.28 M
|
$44.50 M
|
$22.79 M
|
$11.15 M
|
| Interest Income |
$12.79 M
|
$17.74 M
|
$7.04 M
|
$159.00 K
|
$1.93 M
|
$0.00
|
$0.00
|
$0.00
|
| Interest Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Depreciation & Amortization |
$9.11 M
|
$8.28 M
|
$10.60 M
|
$7.72 M
|
$3.58 M
|
$2.33 M
|
$278.00 K
|
$161.00 K
|
| EBITDA |
-$199.47 M |
-$255.18 M |
-$221.88 M |
-$157.44 M |
-$77.78 M |
-$40.80 M |
-$22.51 M |
-$10.99 M |
| EBITDA Ratio |
-74.46
|
-119.8
|
-207.56
|
0
|
0
|
0
|
0
|
0
|
| Operating Income Ratio |
-77.86
|
-123.69
|
-213.24
|
0
|
0
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
$12.79 M
|
$17.72 M
|
$6.85 M
|
$159.00 K
|
$1.93 M
|
$1.37 M
|
$80.00 K
|
$93.00 K
|
| Income Before Tax |
-$195.80 M
|
-$245.74 M
|
-$221.10 M
|
-$165.16 M
|
-$81.36 M
|
-$43.13 M
|
-$22.71 M
|
-$11.05 M
|
| Income Before Tax Ratio |
-73.09
|
-115.37
|
-206.83
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$0.00
|
$678.00 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$80.00 K
|
$0.00
|
| Net Income |
-$195.80 M
|
-$246.42 M
|
-$214.25 M
|
-$160.68 M
|
-$80.33 M
|
-$42.54 M
|
-$22.71 M
|
-$11.05 M
|
| Net Income Ratio |
-73.09
|
-115.69
|
-200.42
|
0
|
0
|
0
|
0
|
0
|
| EPS |
-3.24 |
-4.71 |
-5.16 |
-4.8 |
-2.61 |
-4.73 |
-51.84 |
-25.24 |
| EPS Diluted |
-3.24 |
-4.71 |
-5.16 |
-4.8 |
-2.61 |
-4.73 |
-51.84 |
-25.24 |
| Weighted Average Shares Out |
$60.51 M
|
$52.31 M
|
$41.54 M
|
$33.48 M
|
$30.75 M
|
$9.00 M
|
$438.07 K
|
$437.94 K
|
| Weighted Average Shares Out Diluted |
$60.51 M
|
$52.31 M
|
$41.54 M
|
$33.48 M
|
$30.75 M
|
$9.00 M
|
$438.07 K
|
$437.94 K
|
| Link |
|
|
|
|
|
|
|
|
